Mission Therapeutics – Deubiquitylating enzymes: multiple drug opportu...

Popular pages

• Science – Mission Therapeutics

  Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

• Pipeline – Mission Therapeutics

  Overview Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications. We are currently prioritizing four lead DU...

• Mission Therapeutics authorised to initiate first clinical trial for lead DUB program, MTX652, in

  CAMBRIDGE, UK – 31 March 2022 –Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), toda...

• Careers – Mission Therapeutics

  Careers Mission Therapeutics is a drug discovery and development company engaged in selectively targeting deubiquitylating enzymes (DUBs) with small molecule inhibitors to effectively treat patients w...

• Key Appointments Strengthen Mission Therapeutics’ Senior Management Team – Mission Therapeutics

  CAMBRIDGE, UK– 4 August 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced the promoti...

• About mission – Mission Therapeutics

  Vision Our vision is to transform the treatment of serious diseases by targeting disease-associated deubiquitylating enzymes to harness a new class of drugs. Understanding the complexity of our goal, ...